Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
Top Cited Papers
- 1 February 2013
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 63 (2), 283-295
- https://doi.org/10.1016/j.eururo.2012.10.016
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experienceBJU International, 2012
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladderBMC Medical Research Methodology, 2009
- The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) studyBJU International, 2009
- Clinical guidelines for overactive bladderInternational Journal of Urology, 2009
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-AnalysisEuropean Urology, 2008
- Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 YearsJournal of Cardiovascular Pharmacology and Therapeutics, 2008
- Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerationsBJU International, 2007
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Recent developments in the management of detrusor overactivityCurrent Opinion in Urology, 2003